Join        Login             Stock Quote

iCAD (ICAD) Receives Approval For Digital CAD With Philips Digital Mammography System

 January 07, 2013 10:43 AM

(By Balaseshan) iCAD Inc. (NASDAQ: ICAD) said it has received approval from the U.S. Food and Drug Administration (FDA) for Digital CAD with Philips Digital Mammography System.

The company announced approval for use of its next generation mammography computer-aided detection (CAD) platform, PowerLook Advanced Mammography Platform (AMP), with Digital CAD for Philips' MicroDose Full-Field Digital Mammography System.

PowerLook AMP provides radiologists with the ability to customize their CAD solution to meet the needs of their individual work environment.

The technology expands on iCAD's SecondLook Digital algorithm and is the CAD platform upon which all future breast imaging CAD offerings from iCAD will be built. PowerLook AMP's CAD metrics offer industry-leading tissue and lesion characteristics to support the breast imager's workflow.

[Related -iCAD (ICAD) Receives FDA Clearance Of Cervical Applicator For Xoft Electronic Brachytherapy System]

iCAD's PowerLook AMP's flexible DICOM connectivity solution supports direct integration with Philips' IntelliSpace Breast workstation as well as enabling universal compatibility with leading PACS and Review Workstations. Additional modules are expected to be developed and integrated into PowerLook AMP in the future.

"With this recent FDA approval, we will now be able to offer PowerLook AMP, our next generation digital mammography CAD platform, with the Philips MicroDose Full-Field Digital Mammography System," said Ken Ferry, CEO of iCAD. "This further broadens our partnerships with leading digital mammography companies and provides radiologists with an innovative combination of assessment tools to improve patient care."

[Related -Strong Pre-Election Session]

iCAD, which is headquartered in Nashua, New Hampshire, provides image analysis and workflow solutions that enable radiologists and other healthcare professionals to identify pathologies and pinpointing cancer earlier.

ICAD is trading up 1.70% at $4.79 on Monday. The stock has been trading between $1.75 and $5.12 for the past 52 weeks.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.